Investigator‑Initiated Research (IIR) Program
Ionis Pharmaceuticals' Investigator‑Initiated Research Program funds independent studies advancing science in cardiovascular, hereditary angioedema, and neurological diseases.
Funder: Ionis Pharmaceuticals
Due Dates: Rolling (applications accepted year-round; submit at least 60 days before project start)
Funding Amounts: No preset maximum; award size and duration determined by project scope and available resources.
Summary: Supports independent, investigator-initiated research in cardiovascular/metabolic, hereditary angioedema, and neurological diseases to advance medical knowledge and patient care.
Description
The Investigator‑Initiated Research (IIR) Program from Ionis Pharmaceuticals is designed to support independent, scientifically rigorous research projects conceived and conducted by external investigators and their institutions. The program aims to advance medical and scientific understanding in targeted therapeutic areas, including cardiovascular/metabolic disorders, hereditary angioedema, and neurological diseases such as Alexander Disease and Angelman Syndrome. Research supported by the IIR Program should generate new knowledge relevant to patient care, with priority given to projects that align with Ionis’ research interests, such as observational studies, real-world evidence, disease mechanisms, and patient experience. All research is expected to be ethically conducted and fully independent from commercial considerations.
